Related Experiment Video
Updated: Aug 20, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
Filgotinib in rheumatoid arthritis
1Emeritus Professor KU Leuven, Skeletal Biology and Engineering Research Center Department of Development and Regeneration, Leuven, Belgium.
Expert Review of Clinical Immunology
|November 17, 2022
Summary
Filgotinib, a new Janus kinase inhibitor (JAKi), shows efficacy in Rheumatoid Arthritis (RA) treatment. Its preferential JAK1 inhibition may contribute to a favorable safety profile, though further confirmation is needed.
Area of Science:
- Rheumatology
- Pharmacology
- Immunology
Background:
- Rheumatoid Arthritis (RA) management remains challenging despite advanced strategies.
- Janus kinase inhibitors (JAKi) represent a novel class of targeted oral therapies for RA.
- Filgotinib is a new JAKi approved for RA, with preferential JAK1 inhibition.
Approach:
- This narrative review synthesizes available literature on filgotinib's characteristics, efficacy, and safety in RA patients.
- Detailed analysis of clinical trial data is provided, contextualized for clinical practice and regulatory considerations.
Key Points:
- Preclinical data show preferential JAK1 inhibition and favorable pharmacokinetics with minimal drug-drug interactions.
- Clinical trials indicate increased hemoglobin levels, consistent with JAK1 selectivity over JAK2.
- Phase III trials demonstrate filgotinib's efficacy across various RA disease stages, with a potential dose-dependent effect.
Conclusions:
- Filgotinib exhibits efficacy in RA, with a potentially favorable safety profile, including manageable side effects like herpes zoster and lipid changes.
- The role of preferential JAK1 inhibition in filgotinib's safety profile requires further investigation.
- Long-term safety data in real-world clinical practice are essential for comprehensive understanding.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
211
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
211
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
248
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
248
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:29Drugs for Treatment of Ulcerative Colitis in IBD
219
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
219
01:20The JAK-STAT Signaling Pathway
9.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.1K